Skip to main content
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
Abstract
[This corrects the article DOI: 10.3389/fimmu.2018.01355.].
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.